The Society for Neuro-Oncology (SNO) Annual Meeting is a global event that brings together over 2,600 researchers, clinicians, and scientists from more than 40 countries. Rakovina Therapeutics is a research company focused on the development of innovative cancer treatments, using unique technologies for targeting the DNA-damage response powered by AI. The company aims to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.
Key takeaways:
- Rakovina Therapeutics Inc. is set to present preliminary results of its Deep Docking and generative Artificial Intelligence (AI) drug development program at the Neuro-Oncology Annual Meeting in Houston, Texas on November 22, 2024.
- The poster presentation will highlight the use of Artificial Intelligence in discovering novel PARP1-Selective Inhibitors for use against brain tumors.
- The SNO Annual Meeting is a premier global event in neuro-oncology, attracting over 2,600 researchers, clinicians, and scientists from more than 40 countries.
- Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments, using unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI).